Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
UPDATE 1-Novo Nordisk ties up with Metaphore to develop new obesity drugs [Yahoo! Finance]
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]